CINCINNATI — Procter & Gamble Co. has set up a 24-hour command center and plans to send out a fleet of 1,200 delivery trucks nationwide for its rollout Monday of over-the-counter Prilosec, the heartburn medication.
Don't miss these Health stories
More women opting for preventive mastectomy - but should they be?
Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.
- Larry Page's damaged vocal cords: Treatment comes with trade-offs
- Report questioning salt guidelines riles heart experts
- CDC: 2012 was deadliest year for West Nile in US
- What stresses moms most? Themselves, survey says
- More women opting for preventive mastectomy - but should they be?
The company is hoping Prilosec OTC achieves first-year sales of up to $400 million for what has been a blockbuster seller for its manufacturer, AstraZeneca PLC, as a prescription drug. Prilosec OTC offers consumers a lower-priced option to those versions already on the market, analysts say.
P&G is marketing Prilosec OTC in purple packages and drove a purple van through 24 cities in a “Burntown Challenge” promotion. But the Prilosec OTC tablets themselves are pink — the color of the magnesium salt used to make the tablets.
P&G expects to spend at least $100 million during the first year in marketing Prilosec OTC, including broadcast, print and billboard ads, some featuring a former daytime soap opera star.
Even before P&G gets the product out to retailers, it is facing a competitor’s challenge that its advertising makes false claims. A joint venture between Johnson & Johnson and Merck & Co. has sued P&G in federal court, saying P&G’s ads falsely suggest that the drug cures heartburn in a day.
Johnson & Johnson and Merck said the drug must be taken for 14 days, and the full effect doesn’t begin until the fourth day.
Cincinnati-based P&G responded that its claims are true and consistent with the federally approved packaging for its product. P&G is proceeding with its launch while its lawyers negotiate with the competitor, spokesman Greg Allgood said Friday.
In 2001, Prilosec was the world’s second-biggest selling drug, with revenues of $5.7 billion. U.S. sales totaled $3.7 billion.
The broad trucking distribution and command center is reminiscent of P&G’s all-out effort to quickly ship out Iams pet foods products three years ago when P&G expanded their distribution from specialty stores to general retailers.
William Steele, an analyst with Banc of America Securities, said he expects sales of Prilosec OTC to at least reach $300 million and possibly the top-line forecast of $400 million. That would compare with P&G’s expected total revenues of $49 billion this year and the $650 million annual sales for Actonel, the company’s prescription medicine for treatment of osteoporosis.
Prilosec OTC is the latest entry in an increasingly crowded market for competitors of Prilosec. The $12 billion market for the drugs — known as proton-pump inhibitors, or PPIs — makes it one of the most lucrative drug categories. Other branded versions on the market are Prevacid, Protonix, Aciphex and Nexium.
Prilosec sells for $116 for a month’s supply on Drugstore.com. P&G said Friday it will sell its over-the-counter version for less than $1 per pill.
A German company, Schwarz Pharma AG, began in December selling a generic version of Prilosec, called omeprazole, which costs about $100 for a month’s supply.
Swiss drug maker Novartis AG has said it plans to begin selling a competitor of Prilosec in the United States. Mylan Laboratories, of Canonsburg, Pa., said it may do the same thing.
P&G’s rosy expectations for Prilosec OTC haven’t prompted analysts to increase their prediction that the company will earn $1.23 per share for the quarter that ends Sept. 30. P&G said last week it hopes those earnings will be $1.24 to $1.27 per share.
Under an agreement signed seven years ago, P&G paid AstraZeneca an undisclosed amount of money upfront and will pay an undisclosed royalty to AstraZeneca on sales. AstraZeneca makes the Prilosec OTC tablets and ships them to P&G for marketing and distribution.
© 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.